Scientific Presentations

ATS 2021

Study design of two Phase III, prospective, multicenter, randomized, controlled clinical trials evaluating the efficacy and safety of Liposomal Cyclosporin A for Inhalation (L-CsA-i) in patients with Bronchiolitis Obliterans Syndrome post single- (BOSTON-1) or double- (BOSTON-2) lung transplantation

DownloadDownload PDF of Presentation
ISHLT 2021

Development in lung transplantation, organ shortage, Bronchiolitis Obliterans and overall survival in the US, 2011 -2018
 

DownloadDownload PDF of Presentation
ISHLT 2021

Ensuring Patient Safety And Data Integrity In Clinical Trials for The Treatment Of Bronchiolitis Obliterans Syndrome (BOS) During The COVID-19 Pandemic

DownloadDownload PDF of Presentation
ISHLT April 2021 Presentation

Bronchiolitis Obliterans Syndrome after Lung Transplantation: Economic Burden

DownloadDownload PDF of Presentation
ASH 2020

Lung function monitoring in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients

DownloadDownload PDF of Presentation
ATS 2020

Use Of Functional Respiratory Imaging (FRI) To Explore Drug Delivery And Lung Deposition Of Inhaled Liposomal Cyclosporine A (L-CsA-i) In Patients After Lung Transplantation

DownloadDownload PDF of Presentation
ATS 2020

Pediatric Patients with Bronchiolitis Obliterans Syndrome (BOS): Dosing and Breath Simulation Experiments of Liposomal Cyclosporin A for Inhalation (L-CsA-i)

DownloadDownload PDF of Presentation
EBMT 2020

Prevalence of Bronchiolitis Obliterans Syndrome Following Allogeneic Haematopoietic Stem Cell Transplant in the United States, Europe, and Japan

DownloadDownload PDF of Presentation
ISPOR Orlando 2020

The Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation Patients with Medicare Coverage

DownloadDownload PDF of Presentation
ISPOR Orlando 2020

The Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) in Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Patients with Medicare Coverage

DownloadDownload PDF of Presentation
ISPOR Orlando 2020

Real World Trends in Monitoring Lung Transplant Recipients for Lung Allograft Dysfunction

DownloadDownload PDF of Presentation
ASH Orlando 2019

Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in the United States

DownloadDownload PDF of Presentation
ISPOR Europe Copenhagen 2019

The clinical, humanistic and economic burden of bronchiolitis obliterans syndrome in Europe

DownloadDownload PDF of Presentation
Iacono et al. ERJ Open Research 2019

 

A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation

DownloadDownload PDF of Presentation
NORD Washington 2019

Liposomal Cyclosporine A for Inhalation (L-CsA-i): Innovation in the Treatment of Bronchiolitis Obliterans Syndrome (BOS)

DownloadDownload PDF of Presentation
ERS Madrid 2019

ISHLT Registry Data and Country Registries: Comparison of Reported European/Israeli Lung Transplant Activities in 2016

DownloadDownload PDF of Presentation
ATS Dallas 2019

L-CsA-i, a Liposomal Formulation of Cyclosporine, Demonstrates Therapeutic Potential for Bronchiolitis Obliterans Syndrome (BOS)

DownloadDownload PDF of Presentation
ISHLT Orlando 2019

Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability

DownloadDownload PDF of Presentation
EBMT Frankfurt 2019

Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome (BOS): Novel Formulation With Therapeutic Potential for Patients With BOS Following allo-HSCT

DownloadDownload PDF of Presentation